Advertisement

Topics

Cell Medica Acquires Catapult Therapy for WT1 Cancer Immunotherapy Candidate

09:29 EDT 21 Jun 2017 | Speciality Pharma Journal

LONDON–(BUSINESS WIRE)–Cell Medica today announced the acquisition of Catapult Therapy TCR Limited, a subsidiary of Cell and Gene Therapy Catapult (CGT Catapult), and the initiation of a collaboration to establish cell therapy manufacturing for Cell Medica at CGT Catapult’s GMP manufacturing facility in Stevenage, UK. Financial terms were not disclosed. Catapult Therapy TCR Ltd is …

Original Article: Cell Medica Acquires Catapult Therapy for WT1 Cancer Immunotherapy Candidate

NEXT ARTICLE

More From BioPortfolio on "Cell Medica Acquires Catapult Therapy for WT1 Cancer Immunotherapy Candidate"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...